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Over 1.2 million people in the United States are infected with the human
immunodeficiency virus type 1 (HIV-1). Tremendous progress has been made over the
past three decades on many fronts in the prevention and treatment of HIV-1 disease.
However, HIV-1 infection is incurable and antiretroviral drugs continue to remain the
only effective treatment option for HIV infected patients. Unfortunately, only three out
of ten HIV-1 infected individuals in the US have the virus under control. Thus, majority
of HIV-1 infected individuals in the US are either unaware of their infection status or
not connected/retained to care or are non-adherent to antiretroviral therapy (ART).
This national public health crisis, as well as the ongoing global HIV/AIDS pandemic,
is further exacerbated by substance abuse, which serves as a powerful cofactor at
every stage of HIV/AIDS including transmission, diagnosis, pathogenesis, and treatment.
Clinical studies indicate that substance abuse may increase viral load, accelerate disease
progression and worsen AIDS-related mortality even among ART-adherent patients.
However, confirming a direct causal link between substance abuse and HIV/AIDS in
human patients remains a highly challenging endeavor. In this review we will discuss
the recent and past developments in clinical and basic science research on the effects of
cocaine abuse on HIV-1 pathogenesis.
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INTRODUCTION
The ongoing HIV/AIDS pandemic has claimed around 39 million human lives, and over 35 million
individuals are currently living with HIV-11 infection (Centers for Disease Control and Prevention,
2012). HIV/AIDS research, despite making tremendous strides in the last three decades, is yet to
yield a preventative vaccine. Antiretroviral therapy (ART) continues to remain the sole treatment
option and the current standard of care for HIV-infected individuals (Walensky et al., 2006). ART
has dramatically reduced HIV/AIDS-related mortality and has been highly effective in controlling
the virus in ART-adherent patients (Walensky et al., 2006). Recent studies also suggest that ART
prophylaxis may help reduce transmission of HIV-1 among high-risk groups (Grant et al., 2010;
Cohen et al., 2011; Marrazzo et al., 2015; Siemieniuk and Bogoch, 2015). Despite such advances in
managing the HIV/AIDS disease, latest report from the Centers of Disease Control and Prevention
(CDC) indicate that over two thirds of the 1.2 million living with HIV-1 infection in the US do not
have their virus under control (Centers for Disease Control and Prevention, 2012). Perhaps, a more
1http://www.who.int/mediacentre/factsheets/fs360/en/index.html
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troubling statistic is that, around 20% of those individuals
are unaware of their status (Centers for Disease Control and
Prevention, 2012), which also highlights the challenges in
controlling the HIV epidemic even in a resource rich setting.
The HIV/AIDS crisis is further exacerbated by substance abuse
that serves as a powerful cofactor at every stage of HIV epidemic
including transmission, diagnosis, pathogenesis, and adherence
to therapy (Friedman et al., 2006; Sohler et al., 2007; Cofrancesco
et al., 2008; Kipp et al., 2011). Clinical studies implicate substance
abuse in increased viral load, accelerated disease progression
and worsening of AIDS-related mortality—even among ART-
adherent patients (Anthony et al., 1991; Arnsten et al., 2001,
2002; Friedman et al., 2006; Sohler et al., 2007; Cofrancesco
et al., 2008; Kipp et al., 2011). Therefore, substance abuse
continues to be a major obstacle in combating this global
pandemic. It is increasingly becoming evident that drugs such
as methamphetamine, cocaine, opiates, marijuana, and others
regulate HIV-1 infection/replication in vitro and in animal
models (Wang and Ho, 2011). Furthermore, new research is
shedding light on the negative effects of substance abuse on
immune system that controls viral infections (Wang and Ho,
2011). Overall, these studies are paving ways to better understand
the comorbid condition of drug use and HIV/AIDS. In this
review we will focus on the effects of cocaine abuse on HIV-1
pathogenesis, with a special emphasis on the implications of the
interplay between cocaine and the virus in the brain.
Cocaine Abuse and Mechanism of Action
Cocaine, a commonly used illicit drug, is an alkaloid derived
from the leaves of the coca plant Erythroxylum coca. According
to the National Survey on Drug Use and Health (NSDUH), in
2013, around 1.5million Americans aged 12 and older had abused
cocaine in some form2. Cocaine is a potent vasoconstrictor and
a powerful stimulant of the brain, and abuse of this compound
leads to severe medical complications including neurological
effects (headaches, fainting attacks, hemorrhagic brain strokes,
central nervous system (CNS) vasculitis and encephalopathies),
cardiovascular effects (cardiac arrhythmia and heart attacks),
and gastrointestinal complications (Daras, 1996; Riezzo et al.,
2012; Marasco et al., 2014). Delirium and seizures significantly
contribute to the cocaine-induced morbidity and mortality, while
movement disorders and cognitive motor dysfunction are also
observed in long-term cocaine users (Nnadi et al., 2005). Cocaine
primarily enhances the dopamine neurotransmission in the brain,
thereby causing amplification and reactivity of sensory cues
(Venton et al., 2006; Little et al., 2009). Cocaine directly elevates
the synaptic dopamine levels in the mesocorticolimbic system
by binding to the presynaptic dopamine transporters (DATs)
and inhibiting dopamine reuptake (Ritz et al., 1987; Kalivas and
Volkow, 2005; Marasco et al., 2014). This inhibition is considered
to be the main contributor to the reinforcement and behavioral
properties of cocaine. The elevated dopamine levels in the synaptic
cleft result in increased activation of type 1 and type 2 dopamine
receptors, while the inhibition of dopamine reuptake significantly
contributes to the reinforcement and behavioral properties of
2http://nsduhweb.rti.org/respweb/homepage.cfm
cocaine (Anderson and Pierce, 2005; Schmidt and Pierce, 2006;
Graham et al., 2007). While acute cocaine exposure promotes
dopamine activity, chronic cocaine abuse has been shown to
deregulate striatal dopamine signaling (Willuhn et al., 2014).
Cocaine is also known to block the reuptake of other monoamine
neurotransmitters including norepinephrine and serotonin, and
also impact other excitatory neurotransmitters like glutamate and
its receptors (Howell and Cunningham, 2015).
Effects of Cocaine Abuse on HIV
pathogenesis
Substance abuse is associated with increased HIV transmission,
delayed diagnosis, delayed initiation of therapy, and poor
adherence to therapy, which all constitute important barriers
for combating the HIV pandemic (Khalsa and Royal, 2004;
Cabral, 2006; Friedman et al., 2006; Kipp et al., 2011). Substance
abuse also negatively affects the management of HIV/AIDS as
roughly one-third of HIV/AIDS patients are intravenous drug
users in the United States (Donahoe, 1990). Several studies
have reported associations between drug use and HIV-associated
clinical outcomes, including the Women’s Interagency HIV study
that found substance abuse to be an independent predictor
of progression to AIDS and AIDS-related mortality (Cook
et al., 2008), and the report by Baum et al., suggesting that
substance abuse accelerates HIV disease progression independent
of adherence to ART (Baum et al., 2009). Along with clinical
evidence, experimental studies have shown that illicit drugs such
as amphetamine, marijuana, opiates, nicotine, and cocaine are
associated with immunomodulation and the pathogenesis of
AIDS (Friedman et al., 2003; Pandhare and Dash, 2011). These
drugs cause immunosuppression, modulate the expression of
chemokine receptors on CD4+ T lymphocytes, and influence the
outcome of HIV-1 infection (Battjes et al., 1988; Donahoe and
Falek, 1988; Nair et al., 2000). It is important to point out that there
are also several studies that could not find an association between
substance use andHIV/AIDS (Junghans et al., 1999; Pezzotti et al.,
1999; Chao et al., 2008). Nevertheless, the high prevalence of
substance abuse among HIV-1 infected individuals (Pence et al.,
2008) and the lack of molecular studies warrant further research
to decipher the effects of substance abuse on HIV pathogenesis.
Cocaine Abuse Accentuates HIV-1 Pathogenesis
Cocaine is a commonly abused drug among HIV-1 infected
individuals (Pence et al., 2008) and several studies suggest a link
between cocaine use and worsening of HIV disease (Chaisson
et al., 1989; Anthony et al., 1991; Siddiqui et al., 1993; Larrat
et al., 1996; Cofrancesco et al., 2008; Cook et al., 2008; Baum
et al., 2009; Cook, 2011). There is evidence that cocaine use
results in lack of virologic suppression and accelerated decline of
CD4+ T cells even among ART-adherent patients (Carrico et al.,
2008; Cofrancesco et al., 2008; Cook et al., 2008; Cook, 2011;
Rasbach et al., 2013). For instance, frequent cocaine users exhibit
increased risk of worsening HIV-1 disease progression (Webber
et al., 1999; Vittinghoff et al., 2001), active cocaine and alcohol
use is a strong predictor of failure to maintain viral suppression
(Webber et al., 1999; Arnsten et al., 2001, 2002), and cocaine
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use may result in inferior virologic and immunologic responses
to ART (Lucas et al., 2001, 2002, 2006). However, as mentioned
previously, some studies had found no significant association
between cocaine abuse and HIV-1 disease progression (Pezzotti
et al., 1999; Chao et al., 2008). One potential explanation for
this discrepancy could be that the effects of cocaine on disease
progression may depend in part to non-adherence to ART, as
substance abuse is often associatedwith reduced adherence and/or
access to ART (Hinkin et al., 2007). However, it does not appear
to be the case as evidenced from several studies, wherein, even
when controlled for ART, cocaine users showed higher viral load
and were twice as likely to progress to AIDS (Baum et al., 2009),
were found less likely to suppress their viral load while taking
ART (Palepu et al., 2003), and active cocaine use was associated
with lack of virologic suppression independent of ART adherence
(Rasbach et al., 2013). Although the mechanism remains largely
unclear, increased viral replication and accelerated CD4+ T cell
decline has been suggested to play key roles for the accelerated
disease seen in cocaine abusing HIV-1 patients.
Cocaine Enhances HIV-1 Replication
In vivo studies on the interactions between cocaine and HIV-1
under physiologic conditions have been conducted in a human-
mouse hybridmodel (huPBL-SCIDmouse; Roth et al., 2002, 2005;
Kim et al., 2015). In this model, cocaine administration led to
enhanced HIV-1 infection and a significant rise in circulating
virus load (Roth et al., 2002, 2005; Kim et al., 2015). Several in vitro
studies have also demonstrated the potentiating effects of cocaine
onHIV-1 infection/replication inmonocyte derivedmacrophages
(MDMs; Dhillon et al., 2007), dendritic cells (Napuri et al.,
2013), astrocytes (Reynolds et al., 2006), and peripheral blood
mononuclear cells (PBMCs) (Peterson et al., 1991, 1992; Bagasra
and Pomerantz, 1993). We and others have shown that cocaine
also promotes HIV-1 infection/replication in CD4+ T cells
(Mantri et al., 2012; Kim et al., 2013; Addai et al., 2015). Further,
compared to non-drug users, cells from cocaine addicts readily
supported HIV-1 replication and AIDS-related opportunistic
infections in contrast to cells from non-users (Baldwin et al.,
1998). Studies have reported that immunomodulatory functions
of cocaine may positively contribute to HIV-1 infection and
replication. For example, cocaine has been proposed to negatively
modulate the expression of HIV-suppressing chemokines and
their receptors (Nair et al., 2000; Roth et al., 2005; Reynolds
et al., 2009) in target cells. These include RANTES, MIP-1a and
MIP-1b, which are all known to inhibit binding/fusion/entry of
the virus (Nair et al., 2000, 2001). Furthermore, cocaine has
been reported to upregulate the expression of the viral entry
co-receptors CXCR4 and CCR5 (Nair et al., 2000, 2001), and,
as a result, enhance HIV-1 replication by increasing viral entry.
However, accumulating evidence indicate that cocaine enhances
HIV-1 infection by targeting both entry and post-entry steps of
HIV-1 life cycle (Nair et al., 2000, 2001; Mantri et al., 2012; Addai
et al., 2015).
HIV-1 entry into the target cells is facilitated by the binding
of viral glycoproteins (gp120 and gp41) to the CD4 receptor and
the chemokine co-receptors (CCR5 and CXCR4; Telesnitsky and
Goff, 1997). The ensuing fusion of the viral and cell membranes
leads to the release of the viral capsid core into the cytoplasm
of the target cells (Telesnitsky and Goff, 1997). The subsequent
post-entry events of HIV-1 replication can be broadly categorized
into reverse transcription, integration, transcription, translation,
assembly, virus release and maturation (Telesnitsky and Goff,
1997). We and other research groups have reported that cocaine
can modulate post-entry steps of HIV-1 life cycle (Mantri et al.,
2012; Kim et al., 2013; Addai et al., 2015). Cocaine has been shown
to downregulate the cellular miRNA “miR-125b” in CD4+ T cells
(Mantri et al., 2012). The miR-125b is a member of the of anti-
HIV miRNA family that suppresses HIV-1 replication by binding
to the viral transcripts and inhibiting their translation (Huang
et al., 2007). Cocaine was also recently shown to downregulate
miR-155 that negatively regulates DC-SIGN (Napuri et al., 2013),
which plays a critical role in HIV-1 infection of dendritic cells.
A proteomic study of cocaine-treated human astrocytes revealed
that cocaine differentially regulates an array of cellular proteins,
some or many of which were postulated to potentially modulate
HIV-1 replication (Reynolds et al., 2006). Cocaine’s potentiating
effect on HIV-1 has been partly attributed to the drug-induced
upregulation of sigma-1 receptor, an endoplasmic reticulum-
resident molecular chaperone known to bind cocaine. Cocaine’s
potentiating effect on HIV-1 has been partly attributed to the
drug-induced upregulation of sigma-1 receptor, an endoplasmic
reticulum-resident molecular chaperone known to bind cocaine
(Ramamoorthy et al., 1995; Roth et al., 2005). More recently,
another receptor for cocaine, dopamine D4 receptor (D4R),
was shown to mediate the drug-induced enhancement of HIV-
1 infection in quiescent CD4+ cells, as evidenced by increased
reverse transcription kinetics (Kim et al., 2013). Recently,
our group demonstrated that cocaine increases HIV-1 proviral
integration in CD4+ T cells (Addai et al., 2015). Increased HIV-
1 integration could enhance viral transcription and viral protein
production. Cumulatively, these studies provide strong evidence
that cocaine can modulate both entry and post-entry steps of
HIV-1 infection, thus contributing to increased viral load.
Cocaine’s Effect on CD4+ T cell Decline
CD4+ T cell decline is a powerful diagnostic marker for HIV-
1 disease progression (Embretson et al., 1993; Heinkelein et al.,
1995; Lane, 2010). Studies suggest that cocaine abusing HIV
patients have lower CD4+ T cell counts and accelerated decline in
CD4+ T cell number (Chaisson et al., 1989; Anthony et al., 1991;
Ruiz et al., 1994; Friedman et al., 2006; Cook, 2011). Compared
to non-addicts, individuals addicted to cocaine had significantly
reduced T cell population (Ruiz et al., 1994). Further supportive
evidence comes from animal studies demonstrating that cocaine
decreases the number of circulating lymphocytes (Evans et al.,
1996; Pellegrino and Bayer, 1998; Colombo et al., 1999). There is
also evidence that cocaine modulates the proliferation of human
T cells (Klein et al., 1993; Matsui et al., 1993). Results from in
vitro experiments by our laboratory indicate that when CD4+
T cells were treated with both cocaine and HIV-1 virions, the
extent of CD4+ T cell apoptosis is significantly higher compared
to that of cells treated with cocaine or HIV-1 virions alone
(Pandhare et al., 2014). This suggests that, albeit in cell culture
system, cocaine andHIV-1 act in a synergistic fashion in inducing
Frontiers in Microbiology | www.frontiersin.org October 2015 | Volume 6 | Article 11113
Dash et al. Cocaine abuse and HIV-1 pathogenesis
CD4+ T cell death (Pandhare et al., 2014). While the precise
mechanism by which cocaine synergizes with HIV-1 in the CD4+
T cell decline remains unclear, work done in our laboratory
suggest that increase in reactive oxygen species (ROS) may play
an important role (Pandhare et al., 2014). Furthermore, it was
shown that cocaine downregulates the anti-apoptotic microRNA
“miR-125b” in uninfected and infected CD4+ T cells (Mantri
et al., 2012). miR-125b is a known negative regulator of the pro-
apoptotic gene p53 (Le et al., 2009, 2011), and hence the cocaine-
induced downregulation of this miRNA could potentially play an
important role in the underlying synergy between cocaine and
HIV-1 in CD4+ T cell death. More recently, we also reported
that cocaine directly enhances HIV-1 integration in CD4+ T
cells (Addai et al., 2015). This conceivably could account for the
deleterious effects of cocaine abuse on accelerated CD4+ T cell
apoptosis in HIV-1 patients, because increased viral integration
has been proposed to induce CD4+ T cell apoptosis (Cooper
et al., 2013). Given that both viral load and CD4+ T cell death
are important predictors of HIV-1 disease progression, findings
from our laboratory and others highlight the potentiating effects
of cocaine on HIV-1 disease progression in drug abusing patients.
HIV-1 Infection in the Brain
HIV-1, besides its well-characterized negative effects on the host
immune system through depletion of infectedCD4+ lymphocytes
and immune activation, also broadly impacts the nervous
system (Gonzalez-Scarano andMartin-Garcia, 2005; Spudich and
Gonzalez-Scarano, 2012). During the early phase of infection,
HIV-1 enters the brain and persists in the CNS (Gonzalez-Scarano
and Martin-Garcia, 2005; Spudich and Gonzalez-Scarano, 2012).
Macrophages and microglia are the primary cell types in the
central CNS that can be infected by HIV-1 as well as support
viral replication (Koppensteiner et al., 2012). Although neurons
are refractory to HIV-1 infection, progressive neuronal damage
has been observed in HIV-1 infected patients (Berger and
Nath, 1997; Clifford, 2000; Kaul et al., 2001; McArthur et al.,
2010). HIV-1 infected individuals suffer from a wide range of
neurological disorders. The invasion of the brain by the, leads to
a battery of deficits including reduction in motor speed, decline
in memory and concentration, CNS injury and neuropathy,
which are collectively termed as HIV-associated neurocognitive
disorders (HAND; Woods et al., 2009; Patel et al., 2013; Sanmarti
et al., 2014). From a clinical perspective, HAND is strongly linked
to neurological disorders namely asymptomatic neurocognitive
impairment (ANI), mild neurocognitive disorder (MND), and
HIV- associated Dementia (HAD)- the most severe form of
HAND(Woods et al., 2009; Patel et al., 2013; Sanmarti et al., 2014).
The introduction and the widespread use of ART has managed to
keep the prevalence of HAD in check. However, the incidences
of other milder forms of HAND still persist, are widespread, and
are increasing globally (Gray et al., 2003; Tozzi et al., 2007; Joska
et al., 2010). HAND affects 20–30% patients in the late stages of
AIDS and is believed to be the most common cause of dementia
among people aged 40 or less worldwide (Albright et al., 2003;
Vivithanaporn et al., 2010). Cognitive, motor, and behavioral
dysfunctions are the key phenotypes accompanying neuronal cell
injury and death that result from HIV-1 infection of the nervous
FIGURE 1 | Schematic representation of the BBB. The BBB is made up
of a continuous layer of tightly linked BMVECs. The BMVECs are supported
by the basal lamina, followed by the brain parenchyma that consists of
astrocytes, pericytes, perivascular macrophages, microglia, and neurons.
Each component of BBB plays critical roles in maintaining the selective
permeability of molecules for neuronal homeostasis and protecting the brain
from pathogens and xenobiotics.
system in individuals across various age groups (Woods et al.,
2009; Patel et al., 2013; Sanmarti et al., 2014). In adult patients,
the virus-induced disruption of the nervous system includes
targeted damage to regions beneath the cortex, which significantly
depletes basal ganglia levels (Aylward et al., 1993; Berger and
Nath, 1997). Pathological features of HAND are characterized
by monocyte infiltration into brain, formation of macrophage-
derived multinucleated giant cells, microglial nodules, gliosis,
myelin pallor, and neuronal loss (Gelman, 2015). Both a person’s
age and length of HIV-1 infection are key factors for developing
HAND because prolonged infection accompanied by a decline
in CD4+ T cell count indicates an increased persistence of
the virus in the brain (Tozzi et al., 2007; Brew and Letendre,
2008). Further, co-morbidities such as hepatitis C virus (HCV)
infection and abuse of drugs such as cocaine also increase the
incidence of HAND (Gill and Kolson, 2014; Tedaldi et al.,
2015).
Blood–Brain Barrier
The blood–brain barrier (BBB) is a very dynamic structure critical
for maintaining brain homeostasis and protecting the brain
from pathogens and xenobiotics (Ballabh et al., 2004). The BBB
separates the CNS from the periphery and acts as the interface
between blood capillaries and the brain parenchyma (Ballabh
et al., 2004; Figure 1). The BBB is made up of a continuous layer
of tightly linked brain microvascular endothelial cells (BMVECs)
that is supported by the basal lamina, followed by the brain
parenchyma that consists of astrocytes, pericytes, perivascular
macrophages, microglia, and neurons (Ballabh et al., 2004).
Pericytes are cells of connective tissue that sustain the BBB by
regulating its permeability, capillary blood flow, and phagocytosis
of cellular debris (Ivey et al., 2009). The BMVECs, in combination
with tight junction proteins, form an unperforated endothelium
that confers BBB the selective permeability to peripheral proteins
and other external molecules (Stamatovic et al., 2008; Lv et al.,
2010). Specifically, BMVECs maintain selective permeability
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FIGURE 2 | Effects of cocaine and HIV-1 on BBB integrity and neuronal toxicity. Cocaine and HIV-1 infection has been known to disrupt the integrity of BBB.
This breach in BBB can increase trafficking of infected cells, viral particles and/or viral proteins into the brain causing systemic neuro-inflammation. Ongoing
neuro-inflammation and low level of HIV-1 replication causes neuronal dysfunction and neurotoxicity. Furthermore, drugs of abuse such as cocaine can synergistically
accentuate HIV associated neuronal dysfunction and neurotoxicity leading to worsening of HIV-1 neuropathogenesis.
via the luminal membrane-resident transport systems, which
modulate the efflux and influx of biomolecules through the BBB
(Stamatovic et al., 2008; Lv et al., 2010).
Alterations in the Brain and the BBB by HIV-1
Infection
The CNS is a major target for HIV-1 infection and, because
many antiretroviral drugs display high variability in penetrating
the BBB and reaching therapeutic concentrations, also serves
as a reservoir for the virus (Ivey et al., 2009; Stamatovic et al.,
2008; Lv et al., 2010). The precise mechanism by which HIV-
1 crosses the BBB and causes neuronal dysfunction remains
poorly understood. Findings from animal models and in vitro
studies provide evidence supporting the “Trojan Horse” model
for HIV entry into the brain (Gonzalez-Scarano and Martin-
Garcia, 2005; Ivey et al., 2009; Hazleton et al., 2010). This model
suggests that HIV-1 virions cross the BBB via trafficking of
infected CD4+ cells and monocytes into the CNS (Gonzalez-
Scarano and Martin-Garcia, 2005; Ivey et al., 2009; Hazleton
et al., 2010). Accordingly, infected monocytes cross the BBBmore
efficiently than uninfected monocytes (Persidsky, 1999; Persidsky
et al., 1999). Further, prevalence of increased numbers of non-
proliferating monocytes and brain macrophages in the CNS of
HIV-infected patients is observed as a clinical outcome (Fischer-
Smith et al., 2004). Infected monocytes that have traversed into
the CNS do possess the ability to repopulate as the resident
macrophages (Koppensteiner et al., 2012). Despite some evidence
pointing to HIV-1 entering the brain by direct migration or
transcytosis of endothelial cells through the BBB, the current
prevailing model of CNS infection focuses on infected circulating
monocytes as viral cargos crossing the BBB into the CNS
throughout infection. Once in the brain, HIV-1 can infect
perivascular macrophages and microglia, both of which express
the CD4+ receptor. Astrocytes can be infected but are not a site of
activeHIV replication.Neurons do not express theCD4+ receptor
and thus are not capable of productive infection; therefore,
the HIV-associated neurological complications causing neuronal
damage mainly result from inflammatory factors and neurotoxic
substances released by infected as well as activated, uninfected
cells.
One of the hallmarks of HAND pathogenesis is the breach
of the BBB by infected cells. HIV-1 infection has been shown
to compromise the BBB integrity (Atluri et al., 2015; Figure 2).
Specifically, multiple studies suggest that several HIV-1 proteins
can regulate the permeability of the BBB (Toborek et al., 2005).
For example, administration of the HIV-1 Trans Activator (Tat)
protein, which traverses the BBB potentially by adsorptive
endocytosis (Banks, 2005), in mice led to decreased expression of
occludin and ZO-1 proteins in the tight junction of BBB (Pu et al.,
2007). Further analysis revealed activation of cyclooxygenase
2 (Cox-2) as the mechanistic basis behind the diminished
expression of these tight junction proteins (Pu et al., 2007). In
vitro treatment of various cell types, including BMVEC’S, with
Tat led to increased oxidative stress, which could be attributed
to disruption of tight junctions of the BBB (Shiu et al., 2007). In
astrocytes, Tat reportedly elevates the expression levels of matrix
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metalloproteinase-9 (MMP-9; Ju et al., 2009), a member of the
zinc-dependent endopeptidases known to cleave the extracellular
matrix proteins. Accordingly, MMPs such as MMP-9 have been
reported to disrupt the BBB by degrading the extracellular matrix
proteins such as laminin and type IV collagen (Yong et al.,
1998). Moreover, Tat has been shown to act as a potential chemo
attractant in the BBB milieu, which potentially could alter BBB
integrity. There is also some evidence that Tat acts as a potential
chemo attractant in the BBB milieu that may alter BBB integrity.
The HIV-1 gp120, which mediates viral entry by binding the
CD4 receptor and CXCR4 or CCR5 co-receptor on host cell
surface, has also been reported to breach the BBB. For instance,
treatment of cultured human BMVECs with gp120 increased
monocyte migration and caused a dose-dependent decrease in
transendothelial electrical resistance (TEER; Kanmogne et al.,
2007). These alterations were postulated to be consequences of
increased permeability of BBB caused by the activation of myosin
light chain kinase and/or protein kinase C and increased Ca2+
flux (Kanmogne et al., 2007). Furthermore, in vitro treatment of
human BMVEC’s with gp120 also decreased BBB tight junction
proteins such as ZO-1, ZO-2 and occludin (Kanmogne et al.,
2005; Nakamuta et al., 2008). Exposure of THP-1 monocytes to
gp120 has also been shown to increase secretion of neurotoxins
(Pietraforte et al., 1994). Cytokines could also play a major
role in the gp120-induced alteration of the integrity of BBB,
as evidenced from studies reporting enhanced expression of
pro-inflammatory cytokines due to gp120 treatment in vitro
(Ronaldson and Bendayan, 2006). Besides Tat and gp120, other
HIV-1 proteins have also been implicated in modulating BBB
function (Albright et al., 2003).
Cocaine Abuse and HIV-1
Neuropathogenesis
The complexity of HAND is further exacerbated by co-morbid
conditions such as drug abuse. Cocaine has been suggested to
increase HAND pathogenesis which continues to be a major
challenge in the post ART era (Pakesch et al., 1992; Larrat and
Zierler, 1993; Goodwin et al., 1996; Nath et al., 2001; Ferris
et al., 2008; Norman et al., 2009). HIV-positive cocaine users
are cognitively more impaired and poorly adhere to ART than
their respective non-drug-abusing counterparts (Meade et al.,
2011). Basal ganglia damage that may lead to basal ganglia
dysfunction has been reported in HIV-infected cocaine users
(Newsome et al., 2011). Cocaine is also known to regulate the
rapid activation of the hypothalamic-pituitary-adrenal axis due
to enhanced norepinephrine activity (Torres and Rivier, 1992;
Sarnyai et al., 1996; Manetti et al., 2014). Neurodegeneration and
neuro inflammation are the hallmark features of HAND (Gill
and Kolson, 2014; Rao et al., 2014), and are often exacerbated
in the presence of drugs of abuse such as cocaine (Gannon
et al., 2011; Buch et al., 2012). Brain autopsy studies revealed
significant prevalence of microglia activation, BBB disruption
and infiltration of multinucleated giant cells in drug-abusing
HIV-positive individuals over non-abusing HIV-positive controls
(Gannon et al., 2011). Besides its positive effect on HIV-1
replication in macrophages (Dhillon et al., 2007) and microglia
(Gekker et al., 2006), cocaine use has also been shown to
enhance HIV-1 replication in the normal human astrocytes
(NHAs; Reynolds et al., 2006). Cocaine-exposed, HIV-infected
NHAs exhibited upregulated p24 antigen levels, indicative of high
viral protein content (Reynolds et al., 2006). Though neurons
are generally refractory to HIV-1, persistent and low level viral
infection in the brain triggers production of neurotoxic factors
and release of proinflammatory cytokines and chemokines from
HIV-1 infected macrophages/microglia as well as astrocytes, thus
causing neuroinflammation and neurotoxicity that culminates in
HAND (Gonzalez-Scarano and Martin-Garcia, 2005; Rao et al.,
2014). The plasma and post-mortem brain tissue of HIV-1
infected cocaine users, when compared to that of non-drug users,
displayed elevated levels of the lysosomal protease cathepsin B, a
neuronal pro-apoptotic factor secreted by activated macrophages
(Zenon et al., 2014). This response could be recapitulated
when HIV-infected MDM were exposed to cocaine, thereby
demonstrating that cocaine potentiates cathepsin B secretion and
increases neuronal apoptosis (Zenon et al., 2014). Cocaine abuse
also increases expression of acute phase proteins such as C-
reactive protein (CRP) and serum amyloid A (SAA), which cause
chronic inflammatory effects, including in the brain (Samikkannu
et al., 2013). Thus, cocaine abuse not only facilitates HIV-
1 neuro-invasion via its effect on the BBB but also enhances
neuroinflammation and neurotoxicity observed inHIV-1 infected
individuals. In summary, the interplay between cocaine and
HIV-1 in the CNS mediated via a myriad of pathways, causes
deleterious effects leading to worsening of HAND.
Cocaine Alters Integrity of the BBB
Cocaine, besides being able to passively diffuse through the BBB,
has also been shown to breach the integrity of the BBB by
modulating the structural components of the barrier endothelium
(Sharma et al., 2009). Though the biochemical mechanism
behind this effect awaits delineation, cocaine’s ability to alter the
expression of proteins such as intracellular adhesion molecule
1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and
endothelial-leukocyte adhesion molecule (ELAM or selectin-1)
has been postulated as a key contributory factor (Fiala et al.,
1998, 2005; Kousik et al., 2012). This has been shown, both in
vitro and in rodents, to trigger increased leukocyte migration
across endothelial monolayers, accompanied by elevated levels
of pro-inflammatory cytokines and chemokines such as tumor
necrosis factor alpha (TNF-), nuclear factor kappa B (NFkB),
interleukin 6 (IL-6), and others, ultimately resulting in neuro-
inflammation (Fiala et al., 1998; Chang et al., 2000). In addition,
cocaine up-regulates the pro-migratory CCL2/CCR2 ligand-
receptor system, thereby enabling the HIV-infected monocytes
cross the BBB (Dhillon et al., 2008). In vitro, cocaine binds
to its cognate receptor -1-R in BMVECs and induces the
expression of platelet-derived growth factor (PDGF), both at
the transcript and protein levels, thereby enhancing endothelial
permeability (Yao et al., 2011). Importantly, treatment with PDGF
neutralizing antibodies abrogated this effect in mice (Hata et al.,
2010). Cocaine exposure also leads to BBB deregulation via
the loss or modulation of tight junction proteins. For example,
cocaine downregulates the expression of the tight junction
protein ZO-1 (Dhillon et al., 2008). Furthermore, cocaine is also
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known to upregulatematrixmetalloproteinase (MMP) expression
which triggers reorganization of the basement membrane (Nair
et al., 2005). The ensuing damage to the integrity of the
BBB has been suggested to facilitate the entry of the virus
into the brain. Thus, cocaine-induced alterations in the BBB
integrity can be hypothesized to potentiate HAND pathogenesis
by enhancing HIV-1 neuroinvasion, an outcome facilitated by
increased monocyte entry and neuroinflammation.
Cocaine Exacerbates the Toxicity of HIV-1 Proteins in
the Brain
Cocaine, has been reported to amplify the neurotoxic effects of
HIV-1 proteins such as Tat and gp120 released from the infected
cells, with a magnitude that exceeds that of cocaine or HIV alone.
Both in vitro and in vivo studies have shown that mitochondrial
dysfunction and oxidative stress leading to neuronal cell damage
and death are key factors in exacerbating the effects of cocaine on
the pathophysiology of neurodegenerative disorders. Treatment
of primary rat hippocampal neurons with Tat protein in the
presence of cocaine induced a synergistic effect that enhanced
neurotoxicity (Aksenov et al., 2006). Cocaine also enhanced
the Tat-induced mitochondrial depolarization and generation
of intracellular ROS; Aksenov et al. (2006). Pre-treatment with
a specific dopamine receptor antagonist blocked the cocaine-
induced potentiation of Tat neurotoxicity, thereby underpinning
the role of dopamine receptor-mediated signaling (Aksenov et al.,
2006). Likewise, combinatorial toxicity studies have demonstrated
that exposure of rat primary neurons to both cocaine and gp120
led to increased oxidative stress that was accompanied by an
increase in pro-apoptotic markers (Yao et al., 2009). In another
in vivo study, administering rats with a combination of cocaine
and ventricular injection of HIV-1 gp120 protein resulted in
increased iNOS (nitric oxide synthase) levels accompanied by
neuronal apoptosis in the neocortex region (Bagetta et al., 2004).
Importantly, this effect was ameliorated in animals pretreated
with the iNOS inhibitor, thus substantiating the involvement of
iNOS in HIV-1 gp120 and cocaine-mediated neuronal apoptosis
(Bagetta et al., 2004). Furthermore, treatment of hippocampal
neurons with bothHIV-1 gp120 and cocaine resulted in enhanced
loss of neuronal dendrites (Bagetta et al., 2004). Together, these
studies demonstrate that cocaine augments the effect of HIV-1
Tat and gp120 on neurotoxicity that may contribute to enhanced
HIV-associated neuropathogenesis.
Cocaine Elicits Immuno-modulatory Effects on Brain
Cocaine has multiple physiologic and pathological effects on
various organ systems including the CNS. In general, CNS
comprises of the brain and the spinal cord. Brain is composed
of two major cell types (Glial cells and Neurons) contributing
to its conserved uniqueness in terms of memory, learning
and motor activity. Neurons carry and transmit signals across
specialized synaptic junctions, whereas glial cells maintain the
structural and metabolic homeostasis of the CNS. There is
evidence that cocaine disrupts the homeostasis in the CNS
by exerting toxic and immunomodulatory effects. Persistent
inflammation in the brain due to cocaine abuse has been shown
to involve neuroendocrine interactions. For example, cocaine
modulates secretion of pituitary-adrenocortical hormones that
are immunomodulatory (Rivier and Vale, 1987; Mendelson et al.,
1992). Cocaine can also directly modulate cellular immune
responses by either interactingwith specificmembrane-associated
binding sites or by non-specific interaction with the lymphocyte
plasma membrane (Van Dyke et al., 1976; Klein et al., 1993;
Matsui et al., 1993). Cocaine’s addictive effects are dependent
on the blockage of the DAT and intensification of dopamine
neurotransmission (Ritz et al., 1987; Kuhar, 1992; Woolverton
and Johnson, 1992). Furthermore, dopamine treatment increased
entry of HIV-1 virions into macrophages invoking the possibility
that CNS dopamine may be a common mechanism by which
cocaine may exacerbate neuroinflammation (Gaskill et al., 2014).
In addition to the dopamine system, sigma receptors are also
involved in cocainemediated alterations in immune and neuronal
function (Maurice et al., 2002). The sigma1 (1) receptor, in
particular, has been associated with altered immune functionality
because it is expressed in many cells in the CNS and PBMCs
(Wolfe et al., 1989; Maurice et al., 2002).
Despite advances in understanding the addictive effects of
cocaine, the molecular details behind the immunomodulatory
effects of cocaine in the brain are unclear. Cocaine has been
shown to modulate immune cell activity and secretion of pro-
inflammatory cytokines and chemokines, which together lead
to hypersensitive and perturbed immune responses (Baldwin
et al., 1998; Pellegrino and Bayer, 1998; Clark et al., 2013).
Cocaine users reportedly harbor significantly high numbers
of activated microglia and macrophages (Bowers and Kalivas,
2003; Little et al., 2009), and recent evidence indicates that
cocaine can activate innate immune signaling within the brain.
The innate immune system in brain is comprised primarily
of microglial cells, and cocaine has been shown to activate
the pattern-recognition receptor Toll-like receptor 4 (TLR4)
present on the microglial cells, thereby causing the release of
proinflammatory cytokine interleukin-1b (IL-1b; Northcutt et al.,
2015). These proinflammatory signals contribute to cocaine-
induced changes in the mesolimbic dopamine system and
cocaine reward (Cearley et al., 2011). In addition, cocaine has
been shown to activate astrocytes directly or indirectly through
the microglial proinflammatory response (Bowers and Kalivas,
2003; Coller and Hutchinson, 2012). Upon activation, astrocytes
also release proinflammatory cytokines and glutamate, thus
altering the glutamatergic signaling and neuronal excitability
(Kalivas and Hu, 2006). Chronic cocaine use can cause sustained
activation of microglia and astrocytes, and the ensuing excessive
extracellular glutamate can cause neurotoxicity via glutamatergic
dysregulation. In summary, the immune-modulatory effect of
cocaine can elicit neurotoxic and addictive effects in the brain that
contribute to enhanced HIV-1 induced neuropathogenesis.
Conclusions and Future Prospective
An in-depth understanding of the synergy between HIV-1 and
drugs of abuse such as cocaine is essential to address and
effectively combat the HIV/AIDS global pandemic. Even as ART
has significantly reduced AIDS-related mortalities, averting the
neuro-pathological effects of HIV-1 infection in the brain remains
a daunting challenge. This is all the more urgent for drug users, as
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accumulating evidence suggest that drug use accentuates HIV-1
neuropathogenesis. One major contributor for this exacerbation
is the low-level persistent viral replication in the brain that drives
neuroinflammation. This complex interplay between the virus
and the interfering drugs is further aggravated by the latter’s
inherent excitotoxic potential in targeting the CNS at cellular
and genetic level. Strategies focused on priority areas of action
are indeed required to bolster native brain defense mechanisms
toward nullifying the effects of drugs of abuse on HIV-1
pathogenesis. However, our limited mechanistic understanding
highlights the need of systematic in vivo model systems to
elucidate the cellular circuitries involved in cocaine-mediated
HIV-1 toxicity. On that note, an in-depth analysis of potential
roles of miRNAs in this complex nexus between the virus and
cocaine may yield valuable insights. In addition, whether cocaine
interacts with the wild type and drug resistant HIV-1 differently
that may accentuate disease progression is yet to be determined.
Together, identification of pathways and regulatory molecules
behind the effect of cocaine on HIV-1 pathogenesis could greatly
assist in target selection for therapeutic intervention, in the days
to come.
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